NDAORALCAPSULEPriority Review
Approved
Feb 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
LENVIMA (lenvatinib) by Eisai is receptor tyrosine kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2015.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LENVIMA (lenvatinib) is an oral receptor tyrosine kinase inhibitor approved in 2015 for multiple cancer indications. It works by blocking multiple kinase pathways to inhibit tumor growth and angiogenesis. The drug is administered as an oral capsule and represents a key option in the kinase inhibitor class.
$779MPart D
PeakStable
12.1 years to LOEPeak lifecycle stage with $779M in Part D spending indicates a mature, established commercial infrastructure requiring defensive market share protection and optimization.
Mechanism of Action
Receptor Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Started Oct 2026
35 enrolled
HCC - Hepatocellular Carcinoma
Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer
Started Sep 2026
17 enrolled
Anal Squamous Cell Carcinoma
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer
Started Apr 2026
70 enrolled
Biliary Tract Neoplasms Immunotherapy
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
Started Apr 2026
70 enrolled
Biliary Tract Neoplasms Immunotherapy
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
Started Mar 2026
87 enrolled
Cervical Cancer by FIGO Stage 2018Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2
Worked on LENVIMA at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.